数据日期 2026-10-29 · 生成时间 2026-10-29 06:03
证据级别：摘要级。本条依据 PubMed 结构化摘要与元数据撰写，付费墙全文未获取、未逐节核验，本站未做任何数值推算补全。
研究问题
Polycystic ovary syndrome (PCOS) represents a common endocrine-metabolic disorder.
方法
Mounting evidence has demonstrated that Korean red ginseng confers therapeutic advantages in PCOS; accordingly, this investigation sought to elucidate the therapeutic potential of its bioactive constituent, ginsenoside Rg1, in this pathological condition.
核心结论
A DHEA-induced murine PCOS model was generated for in vivo experiments.；Serum hormonal profiles and insulin sensitivity were assessed.；Ovarian histomorphological alterations were evaluated through hematoxylin and eosin staining.；For in vitro studies, a PCOS-mimicking cellular model was constructed by exposing KGN cells to dihydrotestosterone (DHT, 500nM) for 24h. ‖ 结论：These findings position Rg1 as a promising therapeutic candidate for PCOS management.
局限
未能获取全文，具体设计细节、失访与统计学处理无法核验。
对本项目的价值
★★★☆☆ 生殖衰老提供"衰老速率可被激素轴调节"的天然实验窗口。
原文题录
- 英文标题：Ginsenoside Rg1 alleviates dehydroepiandrosterone-induced polycystic ovary syndrome by regulating granulosa cell glycolysis, proliferative activity, and apoptosis through the PI3K/Akt/mTOR pathway.
- 期刊与标识：Reprod Toxicol · PMID 42946068 · DOI 10.1016/j.reprotox.2026.109394**
B 级证据分级：B 级（同行评议临床前研究，主要为动物模型）
本文核心结论来自动物模型或体外细胞学，属临床前证据，不能外推至人体。「延长健康寿命」「改善功能」等表述在小鼠中的意义，与人类临床结局之间仍有距离。
关于本文的文献来源：本站依据 IMA 知识库「五刊监控·深度文献卡片」（SOP §4.2 摘要级）撰写，依据期刊公开摘要与 PubMed 元数据；付费墙全文未获取之处已标注「待补全文」，未做任何数值推算补全。